NeuroCog Trials, Inc. announces that the MATRICS Consensus Cognitive Battery (MCCB) and the Schizophrenia Cognition Rating Scale (SCoRS) have been chosen as the co-primary outcome measures by a pharmaceutical company to evaluate their novel compound’s pro-cognitive potential among patients
with schizophrenia in an international phase 3 program of clinical trials. NeuroCog Trials, Inc. will provide rater training and data quality assurance for the MCCB and SCoRS for the trials, including their latest video surveillance technology.
Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, said, “We see again that clinical researchers recognize the strong psychometric characteristics of the MCCB, including its robust test-retest reliability, small practice effects, correlations with measures of functional capacity, practicality, tolerability and sensitivity to treatment effects. The acceptance of the SCoRS by regulatory authorities is a noteworthy milestone for NeuroCog Trials, which provides training and quality assurance for the SCoRS. We are also gratified to be chosen to provide support for the MCCB.”
The forthcoming trials will assess several hundred patients at several different time points with the MCCB and the SCoRS. Dr. Keefe added, “this is a crucial set of studies for the development of treatments for cognitive impairment in schizophrenia. The use of video recording technologies for assessments is an important innovation whose time has come for enhancing reliability and sensitivity to treatment in clinical trials.”